Wykorzystanie inhibitorów PDE4 w leczeniu depresji

World Health Organisation. ICD-11 Reference Guide. https://icd.who.int/browse11/content/

refguide.ICD11_en/html/index.html#2.45.06Chapter6MentalDisorders|chapter-06-mental-

behavioural-or-neurodevelopmental-disorders|c2-37-6

http://www.who.int/mediacentre/factsheets/fs369/en/

Parnowski TJ, Łoza B. Nowa Depresja, Nowe Leczenie. Medical Education; 2013.

Kiejna A, Piotrowski P, Adamowski T, et al. The prevalence of common mental disorders in the population of adult Poles by sex and age structure – an EZOP Poland study. Psychiatria Polska. 2015;49(1):15-27. doi:10.12740/pp/30811

https://ezop.edu.pl/wp-content/uploads/2021/12/EZOPII_Rozpowszechnienie.pdf

Pużyński S. Depresje I Zaburzenia Afektywne. PZWL Wydawnictwo Lekarskie; 2018.

Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006;3(11):e442. doi:10.1371/journal.pmed.0030442

Farah WH, Alsawas M, Mainou M, et al. Non-pharmacological treatment of depression: a systematic review and evidence map. Evid Based Med. 2016;21(6):214-221. doi:10.1136/ebmed-2016-110522

Gysin F, Gysin F, Gross F. A depressão do inverno e a fototerapia. Estado dos conhecimentos [Winter depression and phototherapy. The state of the art]. Acta Med Port. 1997;10(12):887-893.

Samochowiec J, Dudek D, Kucharska Mazur J, et al. Leczenie farmakologiczne epizodu depresji i zaburzeń depresyjnych nawracających – wytyczne Polskiego Towarzystwa Psychiatrycznego i Konsultanta Krajowego ds. Psychiatrii Dorosłych. Psychiatria Polska. 2021;55(2):235-259. doi:10.12740/PP/OnlineFirst/132496.

Moncrieff J, Kirsch I. Efficacy of antidepressants in adults. BMJ. 2005;331(7509):155-157. doi:10.1136/bmj.331.7509.155

Gass P, Riva MA. CREB, neurogenesis and depression. Bioessays. 2007;29(10):957-961. doi:10.1002/bies.20658

Gao F, Yang S, Wang J, Zhu G. cAMP-PKA cascade: An outdated topic for depression?. Biomed Pharmacother. 2022;150:113030. doi:10.1016/j.biopha.2022.113030

CARLEZONJR W, DUMAN R, NESTLER E. The many faces of creb. Trends in Neurosciences. 2005;28(8):436-445. doi:10.1016/j.tins.2005.06.005

Yao W, Cao Q, Luo S, et al. Microglial Erk-NRBP1-CREB-BDNF signaling in sustained antidepressant actions of (r)-ketamine. Molecular Psychiatry. 2021;27(3):1618-1629. doi:10.1038/s41380-021-01377-7

Xiao X, Zhang C, Grigoroiu-Serbanescu M, et al. The cAMP responsive element-binding (CREB)-1 gene increases risk of major psychiatric disorders. Mol Psychiatry. 2018;23(9):1957-1967. doi:10.1038/mp.2017.243

Gundersen BB, Briand LA, Onksen JL, Lelay J, Kaestner KH, Blendy JA. Increased hippocampal neurogenesis and accelerated response to antidepressants in mice with specific deletion of CREB in the hippocampus: role of cAMP response-element modulator τ. J Neurosci. 2013 Aug 21;33(34):13673-85. doi: 10.1523/JNEUROSCI.1669-13.2013. PMID: 23966689; PMCID: PMC3755714

Gao F, Yang S, Wang J, Zhu G. cAMP-PKA cascade: An outdated topic for depression?. Biomed Pharmacother. 2022;150:113030. doi:10.1016/j.biopha.2022.113030

Boswell-Smith V, Spina D, Page CP. Phosphodiesterase inhibitors. British Journal of Pharmacology. 2006;147(S1). doi:10.1038/sj.bjp.0706495

Lugnier C. Cyclic nucleotide phosphodiesterase (PDE) superfamily: A new target for the development of specific therapeutic agents. Pharmacology & Therapeutics. 2006;109(3):366-398. doi:10.1016/j.pharmthera.2005.07.003

Fertig BA, Baillie GS. PDE4-Mediated cAMP Signalling. J Cardiovasc Dev Dis. 2018;5(1):8. Published 2018 Jan 31. doi:10.3390/jcdd5010008

Bolger GB. Molecular biology of the cyclic AMP-specific cyclic nucleotide phosphodiesterases: a diverse family of regulatory enzymes. Cell Signal. 1994;6(8):851-859. doi:10.1016/0898-6568(94)90018-3

Houslay MD, Schafer P, Zhang KYJ. Keynote review: Phosphodiesterase-4 as a therapeutic target. Drug Discovery Today. 2005;10(22):1503-1519. doi:10.1016/s1359-6446(05)03622-6

Müller T, Engels P, Fozard JR. Subtypes of the type 4 cAMP phosphodiesterases: structure, regulation and selective inhibition. Trends Pharmacol Sci. 1996;17(8):294-298. doi:10.1016/0165-6147(96)10035-3

Li H, Zuo J, Tang W. Phosphodiesterase-4 inhibitors for the treatment of inflammatory diseases. Frontiers in Pharmacology. 2018;9. doi:10.3389/fphar.2018.01048

Yang F, Sumbria RK, Xue D, et al. Effects of PDE4 pathway inhibition in rat experimental stroke. Journal of Pharmacy & Pharmaceutical Sciences. 2014;17(3):362. doi:10.18433/j3s02v

Delhaye S, Bardoni B. Role of phosphodiesterases in the pathophysiology of neurodevelopmental disorders. Mol Psychiatry. 2021;26(9):4570-4582. doi:10.1038/s41380-020-00997-9

Zebda R, Paller AS. Phosphodiesterase 4 inhibitors. Journal of the American Academy of Dermatology. 2018;78(3). doi:10.1016/j.jaad.2017.11.056

Prickaerts J, Heckman PR, Blokland A. Investigational phosphodiesterase inhibitors in phase I and phase II clinical trials for alzheimer’s disease. Expert Opinion on Investigational Drugs. 2017;26(9):1033-1048. doi:10.1080/13543784.2017.1364360

Śliwiński P., Górecka D., Jassem E., Pierzchała W.: Zalecenia Polskiego Towarzystwa Chorób Płuc dotyczące rozpoznawania i leczenia przewlekłej obturacyjnej choroby płuc. Pneumonol. Alergol. Pol., 2014; 82: 227–263

Goncerz G., Tuchocka-Kaczmarek A.: Leczenie farmakologiczne łuszczycowego zapalenia stawów. Omówienie zaleceń European League Against Rheumatism 2015. Med. Prakt., 2016; 10: 36–42

Bhat A, Ray B, Mahalakshmi AM, et al. Phosphodiesterase-4 enzyme as a therapeutic target in neurological disorders. Pharmacological Research. 2020;160:105078. doi:10.1016/j.phrs.2020.105078

Rutten K, Prickaerts J, Schaenzle G, Rosenbrock H, Blokland A. Sub-chronic ROLIPRAM treatment leads to a persistent improvement in long-term object memory in rats. Neurobiology of Learning and Memory. 2008;90(3):569-575. doi:10.1016/j.nlm.2008.04.016

Fujioka T, Fujioka A, Duman RS. Activation of camp signaling facilitates the morphological maturation of newborn neurons in adult hippocampus. The Journal of Neuroscience. 2004;24(2):319-328. doi:10.1523/jneurosci.1065.03.2004

Li Y-F, Huang Y, Amsdell SL, Xiao L, O'Donnell JM, Zhang H-T. Antidepressant- and anxiolytic-like effects of the phosphodiesterase-4 inhibitor rolipram on behavior depend on cyclic AMP response element binding protein-mediated neurogenesis in the hippocampus. Neuropsychopharmacology. 2009;34(11):2404-2419. doi:10.1038/npp.2009.66

Vecsey CG, Baillie GS, Jaganath D, et al. Sleep deprivation impairs cAMP signalling in the hippocampus. Nature. 2009;461(7267):1122-1125. doi:10.1038/nature08488

Jindal A, Mahesh R, Bhatt S. Type 4 phosphodiesterase enzyme inhibitor, rolipram rescues behavioral deficits in olfactory bulbectomy models of depression: Involvement of hypothalamic-pituitary-adrenal axis, cAMP signaling aspects and antioxidant defense system. Pharmacol Biochem Behav. 2015;132:20-32. doi:10.1016/j.pbb.2015.02.017

Wachtel H. Potential antidepressant activity of rolipram and other selective cyclic adenosine 3',5'-monophosphate phosphodiesterase inhibitors. Neuropharmacology. 1983;22(3):267-272. doi:10.1016/0028-3908(83)90239-3

O'Donnell JM. Antidepressant-like effects of rolipram and other inhibitors of cyclic adenosine monophosphate phosphodiesterase on behavior maintained by differential reinforcement of low response rate. J Pharmacol Exp Ther. 1993;264(3):1168-1178

Hassan G, Kamar SA, Rady HY, Abdelrahim DS, Abdel Hay Ibrahim NH, Lasheen NN. A study of roflumilast treatment on functional and structural changes in hippocampus in depressed Adult male Wistar rats. PLoS One. 2024;19(2):e0296187. Published 2024 Feb 5. doi:10.1371/journal.pone.0296187)

Jindal A, Mahesh R, Bhatt S. Etazolate, a phosphodiesterase 4 inhibitor reverses chronic unpredictable mild stress-induced depression-like behavior and brain oxidative damage. Pharmacol Biochem Behav. 2013;105:63-70. doi:10.1016/j.pbb.2013.01.020

Xie J, Bi B, Qin Y, et al. Inhibition of phosphodiesterase-4 suppresses HMGB1/RAGE signaling pathway and NLRP3 inflammasome activation in mice exposed to chronic unpredictable mild stress. Brain Behav Immun. 2021;92:67-77. doi:10.1016/j.bbi.2020.11.029

Jindal A, Mahesh R, Gautam B, Bhatt S, Pandey D. Antidepressant-like effect of etazolate, a cyclic nucleotide phosphodiesterase 4 inhibitor--an approach using rodent behavioral antidepressant tests battery. Eur J Pharmacol. 2012;689(1-3):125-131. doi:10.1016/j.ejphar.2012.05.051

Guo J, Lin P, Zhao X, et al. Etazolate abrogates the lipopolysaccharide (LPS)-induced downregulation of the cAMP/pCREB/BDNF signaling, neuroinflammatory response and depressive-like behavior in mice. Neuroscience. 2014;263:1-14. doi:10.1016/j.neuroscience.2014.01.008

Yu H, Zou Z, Zhang X, et al. Inhibition of Phosphodiesterase 4 by FCPR03 Alleviates Lipopolysaccharide-Induced Depressive-Like Behaviors in Mice: Involvement of p38 and JNK Signaling Pathways. Int J Mol Sci. 2018;19(2):513. Published 2018 Feb 8. doi:10.3390/ijms19020513

Zhong Q, Yu H, Huang C, et al. FCPR16, a novel phosphodiesterase 4 inhibitor, produces an antidepressant-like effect in mice exposed to chronic unpredictable mild stress. Prog Neuropsychopharmacol Biol Psychiatry. 2019;90:62-75. doi:10.1016/j.pnpbp.2018.10.017

Cong YF, Liu FW, Xu L, et al. Rolipram Ameliorates Memory Deficits and Depression-Like Behavior in APP/PS1/tau Triple Transgenic Mice: Involvement of Neuroinflammation and Apoptosis via cAMP Signaling. Int J Neuropsychopharmacol. 2023;26(9):585-598. doi:10.1093/ijnp/pyad042wang

Wang H, Zhang FF, Xu Y, et al. The Phosphodiesterase-4 Inhibitor Roflumilast, a Potential Treatment for the Comorbidity of Memory Loss and Depression in Alzheimer's Disease: A Preclinical Study in APP/PS1 Transgenic Mice. Int J Neuropsychopharmacol. 2020;23(10):700-711. doi:10.1093/ijnp/pyaa048

Zaki ES, Sayed RH, Saad MA, El-Yamany MF. Roflumilast ameliorates ovariectomy-induced depressive-like behavior in rats via activation of AMPK/mTOR/ULK1-dependent autophagy pathway. Life Sci. 2023;327:121806. doi:10.1016/j.lfs.2023.121806

Alzoubi KH, Mokhemer E, Abuirmeileh AN. Beneficial effect of etazolate on depression-like behavior and, learning, and memory impairment in a model of Parkinson's disease. Behav Brain Res. 2018;350:109-115. doi:10.1016/j.bbr.2018.05.004

Alzoubi KH, Al Subeh ZY, Khabour OF. Evaluating the protective effect of etazolate on memory impairment, anxiety- and depression-like behaviors induced by post traumatic stress disorder. Brain Res Bull. 2017;135:185-192. doi:10.1016/j.brainresbull.2017.10.012

Itoh T, Tokumura M, Abe K. Effects of rolipram, a phosphodiesterase 4 inhibitor, in combination with imipramine on depressive behavior, CRE-binding activity and BDNF level in learned helplessness rats. Eur J Pharmacol. 2004;498(1-3):135-142. doi:10.1016/j.ejphar.2004.07.084

Zeller E, Stief HJ, Pflug B, Sastre-y-Hernández M. Results of a phase II study of the antidepressant effect of rolipram. Pharmacopsychiatry. 1984;17(6):188-190. doi:10.1055/s-2007-1017435

Fleischhacker WW, Hinterhuber H, Bauer H, et al. A multicenter double-blind study of three different doses of the new cAMP-phosphodiesterase inhibitor rolipram in patients with major depressive disorder. Neuropsychobiology. 1992;26(1-2):59-64. doi:10.1159/000118897

Hebenstreit GF, Fellerer K, Fichte K, et al. Rolipram in major depressive disorder: results of a double-blind comparative study with imipramine. Pharmacopsychiatry. 1989;22(4):156-160. doi:10.1055/s-2007-1014599

Bertolino A, Crippa D, di Dio S, et al. Rolipram versus imipramine in inpatients with major, "minor" or atypical depressive disorder: a double-blind double-dummy study aimed at testing a novel therapeutic approach. Int Clin Psychopharmacol. 1988;3(3):245-253. doi:10.1097/00004850-198807000-00006

Guiot-Goffioul F, Gerard-Vandenhove MA, Troisfontaines B, Breulet M, von Frenckell R, Bobon D. Résultats préliminaires d'une étude en double aveugle entre le rolipram et la désipramine chez des déprimés majeurs hospitalisés [Preliminary results of a double-blind study between rolipram and desipramine in hospitalized patients with major depressive symptoms]. Acta Psychiatr Belg. 1987;87(2):230-235.

Scott AI, Perini AF, Shering PA, Whalley LJ. In-patient major depression: is rolipram as effective as amitriptyline?. Eur J Clin Pharmacol. 1991;40(2):127-129. doi:10.1007/BF00280065

https://clinicaltrials.gov/study/NCT04751071?cond=depression&intr=PDE%20inhibitor&rank=4